We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Results of a phase 3 clinical trial which showed that 67 percent of patients treated with the therapy could tolerate up to 600 milligrams of peanut protein with no more than mild to moderate symptoms. Read More
With less than two weeks to go in fiscal 2019, an FDAnews analysis of the FDA’s GMP inspection reports for the year shows that drugmakers continue to stumble at the same old hurdles. Read More
The FDA hit Laboratorio Reig Jofre for numerous violations at its Barcelona sterile drug manufacturing facility, including inadequate smoke studies and failing to qualify contract service providers. Read More
South Korean OTC drug manufacturer Enprani drew a warning letter from the FDA for CGMP violations observed by FDA investigators at its Incheon facility — including the release of products for sale in the U.S. without checking the identity and strength of their active ingredients. Read More
An FDA inspection of Ajinomoto Althea’s San Diego, California sterile drug facility found serious problems with its equipment setup, including a filling machine conveyor belt that caused vials to fall off the belt. Read More
The FDA issued a warning letter to a Costa Rican OTC drug manufacturer for testing and other violations. and , an inadequate stability program and risks of cross-contamination netted a Costa Rican OTC drug manufacturer a warning letter from the FDA. Read More
A Form 483 issued following an FDA inspection of Novartis subsidiary AveXis’ control testing laboratory — currently the focus of a data manipulation investigation by the agency — is raising concerns about the firm’s own investigation and when it knew about the data discrepancies. Read More